The company said Sunday it had received a complete response letter from the Food and Drug Administration concerning its biologics license application. The application sought approval for ivonescimab combined with platinum-containing chemotherapy for patients with locally advanced or metastatic non-small cell lung cancer who had already received certain therapies.
Summit shares had lost about a fifth of their value year to date through Friday’s close. Robert Duggan, the company’s co-chief executive, said Summit was “disappointed for patients and their families awaiting additional treatment options in this setting.”

Comments (0)
No comments yet. Be the first!